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ABSTRACT
MENGBING LI: Extending Dynamic Treatment Regimes to Incorporate Longitudinal
Data Observed Between Decision Times.
(Under the direction of Dr. Michael Kosorok, Thesis Advisor)
Personalized medicine refers to the medical scheme that tailors treatment to individuals
based on individual characteristics, predicted risks, and expected outcomes. Two important
components of personalized medicine involve the estimation of individualized treatment
rules (ITRs) and the design of adaptive clinical trials. Dynamic treatment regimes (DTRs)
are sequential treatment rules for individual patients that are adaptive over their disease
progresses. Much research on estimation of the optimal DTRs has been carried out in the
recent decade, and machine learning methods have been employed in the estimation. It
should be noted that when estimating the optimal DTRs, we usually face the issue of spar-
sity in asynchronously collected data, which standard statistical methods for longitudinal
data may not be applicable. In this thesis, we first review existing two major machine learn-
ing methods, Q-learning and outcome weighted learning, that are applicable to estimating
ITRs with longitudinal data. Then we propose a new learning method that deal with asyn-
chronous sparse longitudinal data when the treatment option is binary. This method uses a
counting process to generate new features, and then utilizes a Q-learning-like approach to
estimate parameters in the decision function. We also discuss advantages and limitations
of the proposed method, as well as possible directions of future research.
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1 INTRODUCTION
Many clinical trials are designed to examine drug effects on the patient population
as a whole in a single stage. However, this unchanged ”one-size-fits-all” scheme can be
problematic in clinical practice because of heterogeneity of patient characteristics and dif-
ferences in patient treatment progression. An ideal optimal treatment regime is expected
to overcome such problems and be individualized and adaptive over time. For example, in
treating patients with psychiatric disorders, clinicians need to consider individual character-
istics which may influence treatment response. Considering the delayed treatment effects
and potential reoccurrence of symptoms, clinicians may also want to relieve the waxing and
waining of patients following long-term treatments, which significantly increase the risks
of severe side effects, psychological and physical stress, as well as economic burden of pa-
tients (Murphy et al. 2006). Therefore, a tailored adaptive treatment design will contribute
to both optimizing treatment effects as well as reducing patient burden.
Dynamic treatment regimes (DTRs), also called adaptive treatment strategies (Murphy
2005), are a general approach to address these concerns. DTRs refer to a sequence of
treatments tailored to a set of covariates, including individual patient characteristics, dosage
level, treatment response, etc. that may or may not be changing over time. Patient status
is reevaluated at each predetermined time point, which breaks up the entire treatment into
many stages, and the treatment given to the patient is decided based on all covariate history
up to that time. The ultimate goal of DTRs is to find a treatment regime that maximizes the
average expected outcome provided that the whole population follow that regime (Kidwell
2015). Under this framework, the one-size-fits-all issue and delayed effects are successfully
addressed. The flexibility and maximal benefit have made DTRs increasingly popular in
clinical practice.
However, although DTRs require patient data collected at each decision point, patient
status and disease progress are not constantly monitored between stages. Additional data
within each stage over time, whether regularly or irregularly collected or not, may aid in
finding better treatment regimes for patients. In a recently conducted study, researchers
appealed to adaptive mobile health (mHealth) to help smokers quit (McClure et al. 2016).
In the study, participants randomized to an adaptive interactive program which provided
real-time, adaptively tailored advice on top of standard self-help content, showed a higher
proportion (76%) of quitting than participants randomized to an non-adaptive program with
standard self-help content (67%). Thus mHealth can serve as a promising intervention to
provide additional data along with treatment in that smart phones are capable of offering
prompt feedback to both smokers and clinicians to make better tailored treatment decisions.
Another example that illustrates the usefulness of collecting additional patient data be-
tween stages is treatment for Type I diabetes (T1D). Young adults with T1D often strug-
gle with glycemic control and weight management (Liu et al. 2010). Compared to other
adults with T1D, those young adults are more likely to experience extra energy loss result-
ing from glucosuria (Anderbro et al. 2010), increased resting energy expenditure (Schober
et al. 2011), as well as increased level of metabolic activity (Wadden et al. 2002) due
to their physiological characteristics. In addition, young adults with T1D are exposed to
an increased risk of weight gain resulting from intense hunger, which is associated with
recurrent hypoglycemia and poor glycemic self-control (Pinhas-Hamiel and Levy-Shraga
2013). Usually, these patients visit physicians on a regular basis and seek feedback and
updated treatment options based on their status at the visit. With the above factors in mind,
monitoring real-time energy expenditure and weight change between their clinical visits is
potentially helpful for physicians to make better decisions on treatments. Thus it can be
expected that collecting additional longitudinal data on patient status is a useful approach
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to optimizing glycemic control and weight management.
Although the scheme may seem promising, carrying out such a process requires many
efforts. On one hand, even though rapidly developing technologies greatly facilitate the
data collection processes through, for example, smart phones, electronic wristbands, and
other portable devices, there is no existing protocol specifying rules and restrictions of the
data collection process. On the other hand, challenges of analyzing the data are significant.
First, finding the optimal DTR usually requires machine learning methods. In (Zhao
et al. 2009), the authors applied reinforcement learning, specifically Q-learning, to discov-
ering the optimal treatment regime in clinical trials for life-threatening diseases. Q-learning
is a model-free temporal difference learning algorithm that deals with infinite-state Markov
Decision Processes (MDP). Rather than learning the MDP, Q-learning instead learns the
value of each state and the optimal policy directly by only using existing states and avail-
able actions in each state. The goal of Q-learning is to optimize the Q-function, which is
the expected discounted reward after executing an action at the current state and following
the policy in all states afterwards. Support vector regression and extremely randomized
trees were used to estimate the Q-function. The method did not rely on precise dynamic
mathematical models, and successfully incorporated delayed effects of treatments, drug
efficacy, and drug toxicity into improving long-term clinical outcomes.
(Zhao et al. 2012) was among the first to use machine learning techniques for clas-
sification in estimating optimal treatment rules. The authors proposed outcome weighted
learning (OWL) in estimating individualized treatment rules (ITR) with binary options. The
method directly finds the optimal ITR that maximizes the clinical outcome using prognostic
variables without modeling the conditional means. (Zhao et al. 2015) proposed two new
nonparametric machine learning methods for estimating the optimal DTR. One is called
backward outcome weighted learning (BOWL), which treats estimating the optimal DTR
as a sequence of weighted classification problems. It starts from the last stage, estimating
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the optimal decision rule in future stages first and then the optimal decision rule in the pre-
ceding stages by restricting analysis to patients who followed exactly all future treatment
rules. The other is called simultaneous outcome weighted learning (SOWL), which sees
estimating the optimal DTR as a single classification problem. It finds the optimal DTR
by directly maximizing the expected average reward. All the above methods are useful in
a standard DTR design, but may not be directly applicable to the newly proposed scheme
where additional longitudinal data are collected between stages.
Second, since we would like to monitor real-time changes in patient status, it is very
likely that data are collected at irregularly spaced time points and are distributed sparsely
(Cao et al. 2015). Given a patient, the sparsity refers to the small number of covariates and
response variables that are observed at the same time, leading to asynchronous data and
violating assumptions for standard methods for analyzing longitudinal data. Thus special
methods such as the one proposed by (Cao et al. 2015) should be considered.
The rest of this thesis is organized as follows. In chapter 2, we introduce individualized
treatment rule for the single-stage and multiple-stage decision settings. We also introduce
the general setting of dynamic treatment regimes with additional data collected between
stages. Each setting will be discussed separately for regularly spaced data and irregularly
spaced data. In chapters 3 and 4, we present Q-learning and outcome weighted learning
respectively, which are existing machine learning methods for estimating the optimal DTR
using. Chapter 5 presents two new algorithms based on outcome weighted learning that
estimate the optimal DTR sequentially and simultaneously, respectively. In chapter 6, we
discuss potential methods to deal with the sparsity in our data. Potential extensions and
future are discussed in chapter 7.
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2 DATA SETTINGS AND NOTATIONS
2.1 Standard Settings
2.1.1 Individualized Treatment Rule in Standard Single-Stage Settings
In the usual standard setting, we only collect patient data at a single time point. We
denote available information of each patient as a tuple (Xn, An, Yn), where n = 1, . . . , N ,
and each tuple is an independent and identically distributed trajectory of (X,A, Y ). Here
X is a p-dimensional random vector of covariates. We consider a setting where treatment
assignments A ∈ A are independent of patient covariates X , where A is the collection
of treatments received. A can be of any form including binary, discrete, and continuous.
Y is the observed clinical outcome, which may also be called the reward depending on
the context, and is coded so that larger values correspond to better outcomes. We assume
Y is bounded. Let D be the collection of all possible treatment rules. An individualized
treatment rule (ITR) is a map d : X → A. An optimal ITR, denoted as dopt, is a rule that
maximizes the expected outcome if implemented by the entire population. Thus our goal
is to quantify the relationship between (X,A, Y ) so that the maximum Y can be achieved.
Depending on the type of treatment assignments, we can apply regression methods, such
as the generalized linear regression, to establish the desired relationship.
2.1.2 Dynamic Treatment Regimes in Standard Multi-Stage Settings
In a K-stage setting, we collect patient data at K decision time points. We can repre-
sent each patient’s available information as (Xn1, An1, Xn2, An2, . . . , XnK , AnK , Yn) where
n = 1, . . . , N and each tuple is an independent and identically distributed trajectory of
(X1, A1, X2, A2, . . . , XK , AK , Y ) sampled at random from a distribution P . Here for each
k = 1, . . . , K, Ak ∈ Ak is the treatment assignment at the kth stage where Ak is the
collection of treatment assignments at stage k. Xk is the available patient information
after treatment assignment Ak−1 but prior to the kth stage. Y is the final outcome after
all stages of treatments and is coded so that larger values correspond to better outcomes.
Let Hk = (X1, A1, . . . , Ak−1, Xk) ∈ Hk be the history information up to stage k with
H1 = X1, andDk be the collection of available treatments at stage k. A dynamic treatment
regime (DTR) is a sequence of decision rules d = (d1, . . . , dK) where each dk is a map
from Hk to Dk. Our goal is to find the optimal DTR dopt that maximizes the expected
average outcome if the rule is implemented by the entire population in the future (Zhao
2015).
We can formalize the process through potential outcomes. We will use lowercase let-
ters ak to denote the realized treatment at stage k. An overbar will be used to denote events
that happened in the past, and an underbar will be used to denote events that will happen
in the future. Thus we have ak = (a1, a2, . . . , ak), and ak = (ak, ak+1, . . . , aK). Note that
d = d. Let X∗(ak) be a patient’s potential covariate status at the start of stage k provided
the sequence of treatments (a1, a2, . . . , ak) was assigned. Let Y ∗(aK) be a patient’s poten-
tial outcome at the end of the study provided the sequence of treatments (a1, . . . , aK) was
followed. In the above framework, we can write h1 = x1, a1 = d1(x1), x2 = X∗(d1) =
X∗(a1), h2 = (x1, a1, x2) = (x2, a1), a2 = d2(h2), x3 = X∗(d2) = X∗(a2), . . . , aK−1 =
dK−1(hK−1), xK = X∗(dK−1) = X∗(aK−1), hK = (xK , aK−1), aK = dK(hK) and Y ∗(aK) =
Y ∗(d) = Y ∗(d). Our optimal DTR will be a rule with the propertyE{Y ∗(d)} ≤ E{Y ∗(dopt)}
for any d ∈ {(d1, . . . , dK) | dk ∈ Dk}.
In order analyze the DTR setup mathematically, we need several assumptions: (1)
causal consistency, or stable unit treatment value assumption (SUTVA) (2) sequential ig-
norability, or no unmeasured confounders, or conditional exchangeability; (3) positivity
(Zhao 2015).
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1. Causal consistency: we assume that the potential outcome under a sequence of treat-
ments is the same as the observed outcome under this sequence of assigned treat-
ments. Mathematically we can express this assumption as for ∀k = 1, . . . , K, if
Ak−1 = ak−1 then Xk = X∗(ak−1), and if AK = aK then Y = Y ∗(aK).
2. Sequential ignorability: we assume that given the history information of patient co-
variates and treatment assignments up to stage k, the treatment assignment at the
next stage k + 1 is independent of potential outcomes of the individual under any
treatment options across all stages. Mathematically, we have ∀ak ∈ Ak, Ak ⊥
{X1, X∗2 (a1), . . . , X∗K(aK−1), Y ∗(aK)} | HK .
3. Positivity: we assume that for any tuples of history information of patient covari-
ates and treatment assignments up to stage k that have a positive probability to be
observed, the corresponding treatment regime will have a positive probability to be
observed. Mathematically, we have ∀k if P [Hk = (xk, ak−1)] > 0, then with proba-
bility 1 P [Ak = ak | Hk] > 0.
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Figure 2.1: Standard data setting for dynamic treatment regimes
2.1.3 Observational Setting
Settings mentioned above are both experimental. However in many circumstances,
observational data play a major role. For example, research on cancers and diabetes are
not likely to involve human experimental data due to ethical issues, and thus studying on
such diseases heavily rely on observational data. Electronic health record (EHR) provides
insightful information for clinical diagnosis and clinical research but is also observational.
There are multiple benefits of using observational data (Kidwell 2015). First, obtaining
observational data is usually the first step to understand disease characteristics and treat-
ment effects. Second, using observational data is less likely to be concerned with ethical
problems, such as research on cancers. Moreover, observational data are generally cheaper
to collect than experimental data. In addition, especially for rare disease, it is more feasible
to use observational data considering the small number of patients.
In order to make causal inference from observational data, we need to check whether
assumptions are satisfied. The sequential ignorability assumption cannot be checked since
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in observational studies, we cannot guarantee that covariate history up to any stage k is fully
available. Besides, statistical methods for adjusting for confounding may not be applicable
to time-varying treatment. Furthermore, deriving unbiased estimates for observational data
is subject to model specification, even though this assumption may be weakened if using
doubly robust methods (Kidwell 2015).
Considering these issues with observational settings, in this thesis we only consider the
simpler settings where the assumptions for standard statistical methods are nicely specified.
2.2 Dynamic Treatment Regimes (DTRs) with Additional Longitudinal Data
2.2.1 Regularly Spaced Data
We consider a setting similar to DTRs with K stages except that additional data are
collected across each stage. In addition to the treatment stages in a DTR, we allow an
optional pre-treatment stage before stage one, which we will call stage 0. No treatment
assignment is made in stage 0, but we may include preliminary patient data before the
first treatment collected through electronic health record or mHealth etc. At each stage
k = 0, 1, . . . , K, patient data are collected atMk randomly selected time points. For k ≥ 1,
we use m = 0 to denote the time when covariates measured right after treatment Ank is
assigned to patient n. To simplify the notations, we also allow m = 0 in the pre-treatment
stage, even though no treatment assignments are made. We assume that covariates of all
patients are measured at the same time, i.e. for each k, we obtain information on covariates
of each patient n at m = 0, . . . ,Mk.
We use a p−dimensional vector Xmnk to represent the available information of patient
n at time m in stage k. For patient n in stage k, the available covariate information
is Xnk = (X0nk, . . . , X
Mk
nk )
T . Data of all patients in stage k will be denoted as Xk =
(X1k,X2k, . . . ,XNk)
T . Let Yn be the final clinical outcome which is coded so that larger
values correspond to better outcomes. Then similar to the standard DTRs, we can represent
each patient’s information as (Xn0,Xn1, An1,Xn2, An2, . . . ,XnK , AnK , Yn)T where each
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tuple is an independent and identically distributed trajectory of (X0, X1, A1, X2, A2, . . . ,
XK , AK , Y ). Let Hk = (X0, X1, A1, . . . , Ak−1, Xk) ∈ Hk be the history information up
to stage k with H1 = (X0, X1), and Dk be the collection of available treatments at stage
k. A dynamic treatment regime (DTR) in this setting, similar to before, is a sequence of
decision rules d = (d1, . . . , dK) where each dk is a map from Hk to Dk. Our goal is again
to find the optimal DTR dopt that maximizes the expected average outcome if the rule is
implemented by the entire population in the future.
To formalize the process through potential outcomes, we can use the same notations as
in standard DTRs, except that x0 is added to all history variables. In addition, we make the
same three assumptions for this modified setting, i.e. SUTVA, sequential ignorability, and
positivity.
Figure 2.2: Data setting for dynamic treatment regimes with regularly spaced additional
longitudinal data
10
2.2.2 Irregularly Spaced Data
In real clinical practice, patients covariates are rarely measured at regular gaps. Instead,
nearly all patients’ measuring time are different. Here we use irregularly spaced data to
refer to the corresponding setting where at least one patient’s covariates are observed at a
different time than other patients’ covariates, i.e. the data are asynchronous. In addition,
given a stage, the number of observations for different patients may be different. Like the
regularly spaced setting, we also allow stage 0, which is the optional pre-treatment stage
before stage one. Suppose for patient n, we measure covariates at timemn = 0, 1, . . . ,Mnk
at stage k. For k ≥ 1, we use m = 0 to denote the time when covariates measured right
after treatmentAnk is assigned to patient n. To simplify the notations, we also allowm = 0
in the pre-treatment stage, even though no treatment assignments are made.
As before, we use a p−dimensional vector Xmnnk to represent the covariates of patient
n at time m in stage k. For patient n in stage k, the available covariate information is
Xnk = (X
0
nk, . . . , X
Mnk
nk )
T . Data of all patients in stage k will be denoted as Xk =
(X1k,X2k, . . . ,XNk)
T . Let Yn be the final clinical outcome which is coded so that larger
values correspond to better outcomes. Then similar to the standard DTRs, we can represent
each patient’s information as (Xn0,Xn1, An1,Xn2, An2, . . . ,XnK , AnK , Yn) where each tu-
ple is an independent and identically distributed trajectory of (X0, X1, A1, X2, A2, . . . , XK ,
AK , Y ). Although the proposed notations lead us to a similar situation to the previous one
where data are regularly spaced, it is dangerous to apply this simple data representation to
our analysis because the data are too sparse for most existing methods to be valid.
Considering the small amount of literature dealing with this complicated situation,
which is closest to the reality, most of our attention in this thesis will be paid to the pre-
vious two multi-stage situations, where the data are not sparse or are regularly spaced for
simplicity.
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Figure 2.3: Data setting for dynamic treatment regimes with irregularly spaced additional
longitudinal data
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3 REINFORCEMENT LEARNING
We first review the statistical methods dealing with the standard DTRs. In treating
life-threatening diseases such as breast cancer and lung cancer, many effective treatments
involves multiple stages that are adaptive to patient performance. There are at least three
challenges for statistical designs of adaptive treatment or trials. First, many existing designs
are based on parametric models to account for efficacy, toxicity, and time to some events.
For example, (Thall et al. 2000) provided a statistical framework for multi-stage treatment
or clinical trials with modifications of the play-the-winner-and-drop-the-loser strategy, in
which a successful treatment is repeated while an unsuccessful one is replaced by another
treatment. Second, as a result of the parametric models, the heterogeneity in treatment
across individuals is ignored and the heterogeneity needed for optimizing individualized
treatment rule is not incorporated. Third, long-term benefits of the treatment or trials are
not successfully evaluated due to delayed effects. Considering these challenges, the authors
of (Zhao et al. 2009) presented a general reinforcement learning framework and related
statistical methods for discovering new treatment regimes.
3.1 Reinforcement Learning and Q-Learning Backgrounds
The basic idea of reinforcement learning is to maximize the outcomes, called the re-
wards in this context, by telling the learning agent whether an action is “good” or “bad”
when it tries among all available actions. In our DTR context, we useX andA to denote the
space of patient covariates and the space of treatments respectively. In the reinforcement
learning context, the random variablesX andA are called “state” and “action” respectively.
Define the time-dependent random variables states Xk = {X0, X1, . . . , Xk} with realized
values xk = {x0, x1, . . . , xk}, and actions Ak = {A0, A1, . . . , Ak} with realized values
ak = {a0, a1, . . . , ak}. The state variables may or may not include past actions, i.e. Xk
may include Ak−1. The distribution P from which the finite longitudinal trajectories are
randomly sampled consists of the unknown distribution of eachXk conditional on previous
(Xk−1, Ak−1) with conditional densities {f0, . . . , fK}. The expectations of the conditional
distributions with respect to the distribution P are denoted as E. For k = 0, 1, . . . , K,
we define the history information up to stage k for a patient as Hk = (Xk, Ak−1). Define
the outcome of a patient’s treatment after stage k as Yk = R(Xk, Ak, Xk+1) = R(Hk+1)
where R is a (possibly random) map from the space of states and actions to the space of
real numbers. The realized value of the reward after stage k is yk = R(xk, ak, xk+1). Our
goal is to find ak to maximize the expected discounted return:
y˜k = yk + γyk+1 + γ
2yk+2 + · · ·+ γKyk+K =
K−k∑
i=0
γiyk+i
where γ ∈ [0, 1] is the discount rate. Intuitively, if γ is closer to 1, the future rewards are
weighted more strongly.
A key element of the reinforcement learning framework is an exploration policy that
maps past states and past actions to the probability that the next action a is taken given
the past states and past actions, i.e. p : hk 7→ pt(a | hk). We can write dk(hk) = ak if
the policy is deterministic but not non-stationary where dk is the decision rule in stage k.
Denote the distribution of training data as Pd when the policy d is used to generate actions,
and the corresponding expectations as Ed. The optimal sequence of treatment, or optimal
policy here, maximizes the expectations with respect to the sum of the rewards over the
time trajectories. We can represent our problem using a value function based on the state
history hk. The value function is the expected total future rewards of a patient conditional
on hk, i.e.
Vk(hk) = Ed
[
K−k∑
i=0
γiYk+i | Hk = hk
]
.
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Then the optimal value function is
V ∗k (hk) = max
d∈D
Vk(hk) = max
d∈D
Ed
[
K−k∑
i=0
γiYk+i | Hk = hk
]
.
In reinforcement learning, value functions are supposed to satisfy some recursive relation-
ships. Therefore we can write the optimal policy dopt as
doptk (hk) ∈ argmax
ak
E
[
Yk + γV
∗
k+1(Hk+1) | Hk = hk, Ak = ak
]
.
In reality, it is common that the optimal policy is not directly computable, and there-
fore the authors suggest using an alternative temporal-difference (TD) learning approach,
specifically Q-learning which estimates a Q-function instead of the value function. Q-
learning is an effective model-free algorithm that allows us to estimate the optimal strate-
gies when we have insufficient knowledge about the distribution of the random variables.
The optimal time-dependent Q-function is
Q∗k(hk, ak) = E
[
Yk + γV
∗
k+1(Hk+1) | Hk = hk, Ak = ak
]
.
Since
V ∗k (hk) = max
ak
Q∗k(hk, ak),
we have the optimal policy satisfying
doptk (hk) = argmax
ak
Q∗k(hk, ak).
One-step Q-learning has the recursive form
Qk(hk, ak) = E
[
Yk + γmax
ak+1
Qk+1(Hk+1, ak+1) | Hk = hk, Ak = ak
]
. (3.1)
15
We let Qˆk be the estimator of the optimal Q-functions for k = 0, 1, . . . , K. According
to (3.1), Qk should be estimated backwards recursively from the last stage to the first stage.
We can let QˆK+1 = 0 for convenience, and obtain QˆK first, then QˆK−1, . . . , Qˆ1, Qˆ0. Each
Qk can be viewed as a function of the states, actions, and a set of time-varying parame-
ters θ, denoted as Qˆk(hk, ak; θ). Once we obtain the sequence of estimated Q-functions
{Qˆ0, Qˆ1, . . . , QˆK}, we are able to estimate the optimal policies via
dˆk = argmax
ak
Qˆk(hk, ak; θ)
for k = 0, 1, . . . , K.
3.2 Estimating the Q-Function
Fitting the Q functions has quite a few challenges. For example, the optimization prob-
lem in (3.1) is not smooth. The dimension of the state variables may be high. Action
variables may also be of high dimension or even continuous. To deal with the difficul-
ties, the authors presented two methods, support vector regression (SVR) and extremely
randomized trees (ERT), for fitting Q-functions and learning the optimal policies.
3.2.1 Support Vector Regression
SVR is a flexible approach for regression problems, and the basic ideas of SVR are
similar to those of SVM. To fit the settings of SVR into a more familiar framework, we
denote the given training data {(zn, yn) ∈ Ω × R : n = 1, . . . , N}, where Ω = {X,A :
X ∈ X , A ∈ A} and R is the real line representing the set of numerical rewards. We define
the attributes znk ∈ Xk×Ak for each n = 1, . . . , N and k = 0, 1, . . . , K. Each total future
numerical outcome ynk.
To guarantee the data are separable when the dimension grows high, the data zn are
first mapped by a non-linear transformation Φ into the feature space. The Q function
acts similarly to a hyperplane f(z) that is fitted to the mapped data. We first suppose
the function f is linear. Let f(z) = wTΦ(zn) + b and the ε-insensitive loss function
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L(f(zn, yn) = (|f(zn) − yn| − ε)+, ε > 0. Other loss functions may also be appropriate.
Then SVR solves the following optimization problem:
min
w,b,ξ,ξ′
1
2
‖w‖2 + C
N∑
n=1
(ξn + ξ
′
n),
subject to wTΦ(zn) + b− yn ≤ ε+ ξn,
yn −wTΦ(zn) + b ≤ ε+ ξ′n,
ξn, ξ
′
n ≥ 0, n = 1, . . . , N,
(3.2)
where ξn and ξ′n are slack variables, and C is the cost of error, also called the tuning param-
eter. The goal of the above setup is to discover a function that has at most ε deviation from
the actual values yn for all training data.
The authors also provide a framework for non-linear kernels. Kernels are a class of non-
negative functions that measure the similarity between features of the individuals, requiring
no knowledge of the non-linear transformation. The kernel function K : Ω × Ω → R is
continuous, symmetric, and positive definite. We can associate with it a unique reproducing
kernel Hilbert space (RKHS)HK which is the completion of the linear span of all functions
{K(·, z) : z ∈ Ω}, with norm induced by the inner product. So we can define K(zi, zj) =
Φ(zi)
TΦ(zj). Equation (3.2) can be rewritten as
min
λ,λ′
1
2
(λ− λ′)TK(zi, zj)(λ− λ′) + ε
N∑
i=1
(λ− λ′) +
N∑
i=1
yi(λ− λ′)
subject to
N∑
i=1
(λ− λ′) = 0, 0 ≤ λi, λ′i ≤ C, i = 1, . . . , N.
Solving for the optimal λ and λ′, we get the approximating function
f(z) =
N∑
i=1
(λ− λ′)K(xi, z) + b.
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3.2.2 Extremely Randomized Trees
The other method to estimate the Q-function mentioned by the authors is the ERT,
which was originally proposed by (Ernst et al. 2005). This nonparametric method uses
random forests and builds each tree by randomizing both attribute and cut-point choice
when splitting a tree node. The parameters include the number of trees, the maximum
number of cut-direction tests at each node, and the minimum number of elements to split a
leaf. See (Ernst et al. 2005) for more details about the algorithm.
3.3 Discussion
To demonstrate the use and effectiveness of the proposed methods, the authors apply
the methods to a simulated sequential multiple assignment randomized trial (SMART).
The result shows that the Q-learning approach using either SVR or ERT performs better in
discovering the optimal policy with roughly equal computational costs.
On discrete state spaces, the proposed method can be applied to any type of treatment,
including for example, continuous dose ranges and binary options. It does not depend on
specific accurate mathematical models. It takes into consideration drug efficacy and toxic-
ity simultaneously and improves the long-term outcomes. The method is also applicable to
high-dimensional attributes with relatively low computational burden. On the other hand,
some potential future improvements include for example, robustness to the model of the re-
ward function, incorporation of patient and physician preference, and addressing reversible
toxicity of the drug.
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4 OUTCOMEWEIGHTED LEARNING
A common approach to estimate individualized treatment rules with binary treatment
options in a one-stage setting is regression. However, most regression-based methods are
parametric or semi-parametric to estimate and optimize the conditional means. (Zhao et al.
2012) proposed a new method to avoid modeling the conditional means, but to estimate
directly the decision rule that maximizes clinical response.
Using the same notations as in previous sections, the proposed method applies to binary
treatment assignments A ∈ A = {−1, 1}, and each patient’s prognostic variables are
X = (X1, . . . , Xp)
T ∈ X . We assume the reward R is bounded and is coded so that larger
values correspond to better clinical outcomes. The optimal ITR is the rule that maximizes
the expected reward if implemented by the entire population. We let the distribution of
(X,A,R) be P and the expectation with respect to P be E. Given any treatment rule d, we
denote the distribution of (X,A, Y ) as P d and the expectation with respect to P d as Ed.
Under the assumption of positivity, i.e. P (A = a) > 0 for A = −1 and 1, we have P d
being absolutely continuous with respect to P and
dP d
dP
=
I{a = d(x)}
P (A = a)
Thus the expected reward under the rule d, also called the value function associated with d,
is
V(d) .= Ed(Y ) =
∫
Y dP d =
∫
R
dP d
dP
dP = E
[
I{A = d(X)}
Api + (1− A)/2Y
]
where pi = P (A = 1). As a result, the optimal ITR is
dopt ∈ argmax
d
E
[
I{A = d(X)}
Api + (1− A)/2Y
]
.
Since we can see in the above formula that the right hand side is location invariant in Y ,
we may assume Y is nonnegative with out loss of generality.
To estimate the optimal ITR, we can equivalently find
dopt ∈ argmin
d
E
[
I{A 6= d(X)}
Api + (1− A)/2Y
]
(4.1)
since Y is assumed to be bounded. The right hand side of (4.1) can be viewed as mini-
mizing a weighted classification error, where each misclassified A using X is weighted by
Y
Api+(1−A)/2 . We would like to find a decision function f such that d(x) = sign{f(x)} with
I{a = d(x)} = I{af(x) > 0}. We can therefore approximate (4.1) by the empirical value
PN
[
I{A 6= sign{f(X)}}
Api + (1− A)/2 Y
]
=
1
N
N∑
i=1
Yi
Aipi + (1− Ai)/2I{A 6= sign{f(Xi)}} (4.2)
where PN denotes the empirical measure of the observed data. However, equation (4.2)
involves minimizing a discontinuous and nonconvex 0-1 loss. One common solution is to
use a surrogate loss function, such as the hinge loss. Then to minimize equation (4.2), we
can instead minimize
1
N
N∑
i=1
Yi
Aipi + (1− Ai)/2(1− Aif(Xi))
+ + λN ‖f‖2 (4.3)
where x+ = max(x, 0) and ‖f‖ is some norm of f .
Linear Decision Rule for Optimal ITR Suppose f is a linear decision function with
f(x) = βTx + β0. The corresponding decision rule to assign a patient with prognostic
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value X to treatment 1 is βTx + β0 > 0 and −1 otherwise. We let the norm in equation
(4.3) be the Euclidean norm. Following the usual SVM, we can rewrite equation (4.3) as
max
β,β0,‖β‖=1
C
subject to Ai(βTx+ β0) ≥ C(1− ξi),
ξi ≥ 0,
∑ Ri
pii
ξi < s,
(4.4)
where C > 0 is the classifier margin, pii = piI{Ai = 1} + (1− pi)I{Ai = −1} = P (A =
1|Xi) and s is a constant depending on λN . Note that equation (4.4) is equivalent to
min
1
2
‖β‖2 + κ
N∑
i=1
Ri
pii
ξi
subject to Ai(βTx+ β0) ≥ (1− ξi),
ξi ≥ 0,
where κ is a tuning parameter. After introducing Lagrange multipliers and algebraic ma-
nipulations, we obtain a dual problem
max
α
N∑
i=1
αi − 1
2
N∑
i=1
N∑
j=1
αiαjAiAjX
T
i Xj
subject to 0 ≤ αi ≤ κRi/pii, i = 1, . . . , N,
N∑
i=1
αiAi = 0.
(4.5)
This dual problem involves a quadratic objective function. Finally we obtain
βˆ =
∑
αˆi>0
αˆiAiXi,
and estimate βˆ0 using the marginal points (0 < αˆi, ξˆi = 0).
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Nonlinear Decision Rule for Optimal ITR In most cases the decision rule is likely to
be nonlinear due to the complicated structure of the space of prognostic variables. We use
the kernel function K, as introduced in section 3.2.1, to find the decision function f . Since
f(x) comes from the associated RKHS HK , it can be written as a linear combination of
K(·, x), i.e. f(x) = ∑mi=1 αiK(·, xi). We can show that the optimal decision function is
given by
N∑
i=1
αˆiAiK(X,Xi) + βˆ0,
where (αˆ1, . . . , αˆN) solves the same dual problem as in equation (4.5)
The authors also establish several properties of the optimal ITR estimated by OWL.
First, the risk associated with the optimal decision rule under 0-1 loss is the Bayes risk.
Second, Fisher consistency is established to justify the validity of using the surrogate loss
function, hinge loss, in OWL. Third, the excess risk of f under 0-1 loss is no larger than
the risk of f under hinge loss. Fourth, the value of the estimated optimal decision function
fˆN is a consistent estimator of the true optimal value function.
OWL is the first to introduce machine learning methods that directly estimate the opti-
mal ITR without appealing to any accurate mathematical models of the conditional means.
It also avoids overfitting compared to other two-stage methods. Furthermore, the conver-
gence rate of OWL is nearly the optimal for nonparametric SVM on completely separated
data.
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5 BACKWARD AND SIMULTANEOUS OUTCOMEWEIGHTED LEARNING
In previous sections, we introduced Q-learning for estimating the optimal dynamic
treatment regime. It estimates the Q-functions using the data first, and then maximizes
or minimizes the function to infer the optimal DTRs. However, this two-step regression-
based method encounters some issues when facing high-dimensional data. To resolve such
issues, (Zhao et al. 2015) proposed two new dynamic statistical learning approaches to
estimating the optimal DTR. One method is called backward outcome weighted learning
(BOWL), which treats optimal DTR estimation as a sequence of weighted classification
problems. It uses outcome weighted learning to identify a sequence of optimal decision
rules in a backward recursive fashion. The other method is called simultaneous outcome
weighted learning (SOWL), which treats optimal STR estimation as a single classification
problem. It uses outcome weighted learning to identify the optimal decision rules at all
stages simultaneously.
5.1 Backward Outcome Weighted Learning (BOWL)
We suppose the three assumptions for DTRs with experimental data hold: causal con-
sistency, sequential ignorability, and positivity. The treatment option is binary Ak ∈ A =
{−1, 1}. Covariate history up to stage k is denoted with an overbarXk = {X0, X1, . . . , Xk},
with realized values xk = {x0, x1, . . . , xk}. The actions taken up to stage k is denoted as
Ak = {A0, A1, . . . , Ak} with realized values ak = {a0, a1, . . . , ak}. Similar to outcome
weighted learning in the previous chapter, we would like to maximize the value associated
with a decision rule d, which is
V(d) =
∫
Y
dP d
dP
dP = E
[
Y
∏K
j=k+1 I{Aj = dj(Hj)}∏K
j=k pij (Hj, Aj)
]
. (5.1)
The idea behind BOWL is through backward estimation based on future optimal de-
cision rules that are available. Suppose that we have obtained all optimal treatment rules
after stage k, denoted as doptk+1 = (d
opt
k+1, . . . , d
opt
K ). Then the optimal decision rule at stage k
should maximize
E
[
Y
∏K
j=k+1 I{Aj = doptj (Hj)}∏K
j=k pij (Hj, Aj)
I{Ak = dk(Hk)}
∣∣∣∣∣Hk = hk
]
.
This places the constraint that we only consider patients who follow exactly the optimal
treatment regime in all stages after the k-th stage. Equivalently, the optimal treatment
regime dopt is a map from Hk to {−1, 1} that minimizes the empirical analogue of the
above expression:
E
[
Y
∏K
j=k+1 I{Aj = doptj (Hj)}∏K
j=k pij (Hj, Aj)
I{Ak 6= dk(Hk)}
]
. (5.2)
This can be viewed as an optimization problem with 0-1 loss or a weighted misclassification
problem, where the weights are defined by
Y
∏K
j=k+1 I{Aj = doptj (Hj)}∏K
j=k pij (Hj, Aj)
.
To develop an estimation procedure, the authors replace the 0-1 loss function with a convex
surrogate loss function φ(t). Let fk : Hj → R denote the decision function in stage k, so
that dk(hk) = sign(fk(hk)). Then we can minimize the following expression with respect
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to fk:
PN
[
Y
∏K
j=k+1 I{Aj = doptj (Hj)}∏K
j=k pij (Hj, Aj)
φ (Akfk(hk))
]
+ λk,N ‖fk‖2 , (5.3)
where λk,N is a tuning parameter controlling the amount of penalization. Since we do not
know the future optimal DTR, we need to estimate the decision function from the last stage
and proceed backwards. The BOWL algorithm is presented as follows:
Algorithm 1 BOWL
Input: Patient history up to stage k : Hk = (Xk, Ak−1)
Output: Decision rule dk at stage k
1: for k ← K,K − 1, . . . , 1 do
2: if k = K then fˆk ∈ argminfk
{
PN
[
Y
pik(Hk,Ak)
φ (Akfk(hk))
]
+ λk,N ‖fk‖2
}
3: dˆk(hk)← sign(fˆk(hk))
4: elsefˆk ∈ argminfk
{
PN
[
Y
∏K
j=k+1 I{Aj=dˆj(Hj)}∏K
j=k pij(Hj ,Aj)
φ (Akfk(hk))
]
+ λk,N ‖fk‖2
}
5: dˆk(hk)← sign(fˆk(hk))
6: end if
7: end for
In the above algorithm, the minimization problem is similar to that in outcome weighted
learning in the previous section.
5.2 Simultaneous Outcome Weighted Learning
Unlike BOWL which estimates the optimal decision rules sequentially, SOWL com-
pletes the task at all stages simultaneously. However, maximizing (5.1) involves a discon-
tinuous, non-convex 0-1 loss function, which may cause computational complexity. For
k = 1, . . . , K, let Zk = Akfk(Hk). In SOWL, noticing that
∏K
j=k+1 I{Aj = dˆj(Hj)} is
equivalent to
∏K
j=k+1 I {Zk > 0}, the authors replace the 0-1 loss function with hinge loss
ψ(Z1, . . . , ZK) = min(Z1 − 1, . . . , ZK − 1, 0) + 1, which is smooth and concave. Then
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the objective function to maximize is
PN
[
Y ψ(Z1, . . . , ZK)∏K
j=k pij (Hj, Aj)
]
− λN
K∑
k=1
‖fk‖2 , (5.4)
where λN is a tuning parameter controlling the amount of penalization. The detailed com-
putational algorithm is presented in (Zhao et al. 2015) and we will omit the details here.
5.3 Discussion
Both BOWL and SOWL aim at maximizing directly the expected long-term outcome.
Compared to regression-based Q-learning, they are more robust because they do not rely-
ing on models of the Q-function for the optimal DTRs. When the number of stages is large,
SOWL may face som numerical instability because is involves defining a multi-dimensional
surrogate loss. In this case, BOWL may have more benefits. On the other hand, SOWL al-
lows one to examine the estimation at the same time rather than sequentially using BOWL.
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6 PROPOSED METHODOLOGY FOR ADDITIONAL LONGITUDINAL DATA
The main purpose of this section is to provide a genuine framework for estimating
the optimal individualized treatment regime when sparse asynchronous longitudinal data
are present. Here we only consider binary treatment options A ∈ A = {−1, 1} in a
randomized study. We assume that patient covariates are time-varying and can be viewed
as a function of time, i.e. X = X(t), and therefore patient history can also be viewed as
a time-varying variable Hk(t) = (X(t)0, X(t)1, A1, . . . , Ak−1, X(t)k) ∈ Hk. To define
the optimal ITR, we make the same three assumptions for dynamic treatment regimes: (1)
causal consistency; (2) sequential ignorability; and (3) positivity. Define
Q(h, a) = E[Y | H(t) = h(t), A = a].
To model on the conditional mean, we will fit a linear model with the intercept of the
form
E [Y | H(t) = h(t), A = a] = α + βTh(t) + a{γ + δTh(t)}, (6.1)
where α and β are unknown regression parameters of the main effects, and γ and δ are
unknown regression parameters of the interaction effects.
The basic idea behind our methodology is to apply a counting process approach to
generate new features using a set of basis functions in each stage, and the optimal treatment
rule is estimated with the new features by a Q-learning-like procedure. We use a counting
process for the observation times of the covariates to represent the asynchronous data of
our setting. In stage k for each patient n = 1, . . . , N , define
Fnk(t)
.
=
Mnk∑
j=1
I{T jnk ≤ t} (6.2)
where T jnk, j = 1, . . . ,Mnk are the observation times for the covariates in stage k and
Mnk <∞with probability 1. Thus the actual observations on the covariates areX(T 1nk), . . . , X(TMnknk ).
For each stage k = 1, . . . , K, let Ψk = {Φkl(t; θkl) : θkl ∈ Θ, l = 1, . . . , Lk} be a
collection of normalized basis functions chosen to model patient covariates X(t). Each
Φkl(·; θkl) is indexed by an unknown parameter θkl, either a vector or a scalar, in the
parameter space Θ. We require each Φkl(·; θkl) be of the form φ(·;θkl)c(θkl) where c(θkl) is a
constant that averages the effect of the chosen basis function on the covariates over the
entire time period with respect to the counting process. If the basis function is a ker-
nel function, then ckl(θkl) =
∫
Φkl(t; θkl)dFnk(t). Take the radial basis function ker-
nel ΦRBF (t; θ) = c(θ)exp(−θ ‖t− t′‖)2 as an example, which downweights the obser-
vations made distant in time to a given time point t′. Assuming time t ≥ 0, c(θ) =∫∞
0
exp(−θ ‖t− t′‖)2dt = √pi
θ
Φ(
√
2θt′) where Φ here is the standard normal cumula-
tive distribution function. On the other hand, if the basis function is a natural basis, then
ckl(θkl) =
∫
dFnk(t). These bases include cos(θt), sin(θt), and a+ θt, etc. The basis func-
tions are to be chosen by the investigator depending on the research questions of interest as
well as data structure.
We now begin to construct new features for each patient’s covariates using Lk basis
functions. We view the new feature as a function of the parameter θl by defining
X˜ lnk(θkl)
.
=
∫
Φkl(t; θkl)Xnk(t)dFnk(t) (6.3)
with appropriate choice of bandwidth. The intuition behind the above definition is that
given a time t, each new feature contains more information about the covariate observations
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made before and close in time to t, than those made after or distant in time to t. This allows
for using all covariate information we observe but focusing on time points of more interest.
Let θk = (θk1, . . . , θkLk). We use
Unk(θk) = (X˜
1
nk(θ1), . . . , X˜
Lk
nk (θLk))
T
to denote the vector of new features of patient n in stage k, generated using the collection
of kernels in Ψ. We also denote the collection of new features of all patients in stage k
by Uk(θ) = (U1k(θ), . . . , UNk(θ))T . As before, we use an overbar to denote events that
happened in the past, so Uk(θ) = (U1(θ1), . . . , Uk(θLk)). The history data up to stage k
with the new features is then denoted as H˜k(θ) = (Uk(θ), Ak−1).
As in reinforcement learning which was described in Chapter 3, One-step Q-learning
has the recursive form
Qk(h˜k(θ), ak) = E
[
Yk + max
ak+1
Qk+1(H˜k+1(θ), ak+1) | H˜k(θ) = h˜k(θ), Ak = ak
]
, (6.4)
where Yk = Y if k = K and Yk = 0 otherwise in our case.
We let Qˆk be the estimator of the optimal Q-functions for k = 0, 1, . . . , K. According
to (6.4), Qk should be estimated backwards recursively from the last stage to the first stage.
We can let QˆK+1 = 0 for convenience, and obtain QˆK first, then QˆK−1, . . . , Qˆ1, Qˆ0. Note
that the estimated Q-values are functions of the unknown parameter µ = (α, β, γ, δ, θ)T ,
and we would also like to obtain estimates µˆk = (αˆk, βˆk, γˆk, δˆk, θˆk) of the parameter. We
may estimate the parameter using least-square simultaneously when estimating the optimal
policy, so then
µˆk ∈ argmin
µ
PN
[
Yk + max
ak+1
Qˆk+1(H˜k+1(θ), ak+1; µˆk+1)−Qk(h˜k(θ), ak;µ)
]2
(6.5)
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Notice that
max
ak+1
Qˆk+1(H˜k+1(θ), ak+1; µˆk+1)
= max
ak+1
[
α + βT h˜k+1(θ) + a{γ + δT h˜k+1(θ)}
]
=α + βT h˜k+1(θ) +
∣∣∣γ + δT h˜k+1(θ)∣∣∣ .
Plugging in the linear model, we can rewrite the estimating procedures in (6.5) as:
When k = K + 1,minµ PN
(
Y − α− βT h˜k(θ)− ak{γ + δT h˜k(θ)}
)2
;
When k ≤ K,
min
µ
PN
(
αˆk + βˆ
T
k h˜k(θ) +
∣∣∣γˆk + δˆTk h˜k(θ)∣∣∣
−αk−1 − βT h˜k−1(θ)− ak−1{γk−1 + δTk−1h˜k−1(θ)}
)2
.
(6.6)
After obtaining parameter estimates µˆk for all k = 1, . . . , K, the optimal decision rule
for each stage can be estimated by
dˆk
(
H˜k = h˜k
)
= sign
(
γˆk + δˆ
T
k h˜k(θˆk)
)
.
In order to determine our basis functions, the parameter θ is required to be identifiable,
which means the one-to-one correspondence between the parameter and the basis function.
Following our notation, we can express identifiability as Φ(t; θ) = Φ(t; θ0) ∀t if and only
if θ = θ0. In some cases, the parameter θ may not be identifiable if we do not restrict the
range of the parameter space. Consider the example of a linear basis Φ(t; a, b) = a+ bt. To
construct a new feature by (6.3), we calculate X˜ =
∫
(a + bt)X(t)dF (t). However, when
estimating the parameters using (6.6), there may be multiple solutions to (a, b). One way
to resolve this issue is to restrict the solution (a, b) to the unit circle using parametrization
a = sin(θ), b = cos(θ), where θ ∈ [0, 2pi). The actual way of ensuring identifiability
depends upon the form of the chosen basis functions.
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7 DISCUSSION
In this thesis, we introduced individualized treatment regimes in single-stage and multi-
stage settings, and a new setting where each patient’s data are not collected at the same time.
We described three types of recently developed machine learning method to estimate the
optimal treatment rules in single-stage settings and dynamic treatment regimes. First, we
introduced a regression-based nonparametric reinforcement learning method, Q-learning,
which estimates the optimal decision rule by directly maximizing the Q-function sequen-
tially backwards. Second, we reviewed outcome weighted learning for estimating indi-
vidualized treatment rule in single-stage settings with binary treatment options. Third, we
presented two nonparametric extensions of outcome weighted learning to dynamic treat-
ment regimes. Backward outcome weighted learning and simultaneous outcome weighted
learning estimate the optimal DTR directly by maximizing the long-term expected outcome
over all possible DTRs.
We proposed a novel machine learning method to estimate the optimal DTR using
sparse asynchronous data from a sequential randomized trial when the treatment option
is binary. The method effectively deals with sparsity in asynchronous data by employing
a counting process on patient covariates, and constructing new features with basis func-
tions. It can handle the potentially complex structure in autocorrelation of covariates. We
postulated a linear model on the expected long-term outcome given covariate history and
treatment history, and applied Q-learning for estimation. Parameter estimation was com-
pleted through sequential backward least-square regression and the optimal decision was
determined by the sign of the decision function.
However, our method may be subject to model misspecification, which may affect con-
sistency of the estimates and stability of the method. Such misspecification may come
from choices of basis functions and modeling of the conditional mean. Some of the con-
cerns with potential model misspecification can potentially be addressed through extending
the proposed longitudinal data approach to outcome weighted learning, including BOWL
and SOWL, which is a good topic for future research. In addition, we assume the data we
have are experimental. Applying this method to observational data may require modify-
ing some assumptions on causal relationships of the covariates. Moreover, we also expect
some future work to test the proposed method on simulated data and real data. Extending
the treatment option from binary to multiple discrete options and continuous options is also
a promising direction for future research.
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